This small-cap Healthcare stock engaged in operating multi-specialty hospitals, offering healthcare services, outpatient diagnostics, emergency care, and specialized treatments across the National Capital Region, is in focus after AnandRathi gave a target of Rs. 590, which has an upside potential of 45 percent.
With a market capitalization of Rs. 3,738.42 crore, the shares of Indraprastha Medical Corporation Limited closed at Rs. 407.80 per equity share, down nearly 1.34 percent from its previous day’s close price of Rs. 413.35.
AnandRathi, a prominent brokerage firm, has recommended a “Buy” call on Indraprastha Medical Corporation Limited with a target price of Rs. 590 per share, indicating an upside potential of 44.68 percent.
Anand Rathi has given a positive view on Indraprastha Medical Corporation Limited, driven by two key catalysts. First, the promoters are in talks to buy part or all of the Delhi government’s 26 percent stake. It would give the company greater control over decision-making and more freedom to raise funds. That, in turn, could fuel faster growth within the NCR and support expansion into new regions, boosting revenues and market reach.
Second, the planned capacity expansion at Sarita Vihar will add 350 beds to reach 1,150 by mid-CY28. This Rs. 5.8 billion project, 40 percent of which will be spent in FY26, also includes two underground parking levels for over 1,300 cars and 350 two-wheelers. The enlarged, modern facility is expected to strengthen Indraprastha’s leadership and improve its profitability over time.
Indraprastha Medical Corporation Limited operates Indraprastha Apollo Hospitals, a leading multi-specialty tertiary care hospital in New Delhi. The company was established in 1988 and offers advanced medical services supported by cutting-edge technology and expert staff, delivering high-quality healthcare in India’s capital.
The hospital currently has a capacity of 802 beds, including the maximum number of ICU beds in a private hospital in India. The hospital is spread over 15 acres with a built-up area of over 600,000 square feet.
The last major expansion added 127 beds, including single rooms, general ward beds, and ICU beds. The hospital is continuously upgrading to meet increasing patient demand and incorporate new technologies.
Coming into financial highlights, Indraprastha Medical Corporation Limited’s revenue has increased from Rs. 315 crore in Q4 FY24 to Rs. 334 crore in Q4 FY25, which has grown by 6.03 percent. The net profit has also grown by 32.26 percent, from Rs. 31 crore in Q4 FY24 to Rs. 41 crore in Q4 FY25.
Indraprastha Medical Corporation Limited’s revenue and net profit have grown at a CAGR of 15.15 percent and 39.74 percent, respectively, over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 39 percent and 30 percent, respectively. Indraprastha Medical Corporation Limited has an earnings per share (EPS) of Rs. 17.6, and its debt-to-equity ratio is 0.05x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
